Systemic safety analysis of mycophenolate in Graves ’ orbitopathy
ConclusionThe risk –benefit ratio of low-dose mycophenolate treatment in active moderate-to-severe GO is highly favorable given its reassuring safety profile with low rate of mild-to-moderate SE and promising efficacy.
Source: Journal of Endocrinological Investigation - Category: Endocrinology Source Type: research
More News: Autoimmune Disease | China Health | Databases & Libraries | Endocrinology | Gastroenterology | Liver | Liver Transplant | Sodium | Toxicology | Transplants | Urology & Nephrology